Preclinical pipeline overview / Help fund a movie about AMR!

Dear All: Two things today.

First, Ursula Theuretzbacher, Miloje Savic, Christine Ardal, and Kevin Outterson have published in Nature Reviews Drug Discovery a brief but instructive snapshot of the global preclinical antibacterial pipeline. This report nicely complements the recent WHO analysis of the clinical pipeline that concluded that “the world is running out of antibiotics.”

You’ll want to read the paper yourself (it’s brief and open access), so I’ll just summarize by saying that Ursula and colleagues have analyzed applications from Year 1 of the CARB-X initiative, found a good diversity of approaches, and observed that this shows an encouraging alignment with the WHO priority pathogen list. This is encouraging, but these preclinical programs have still a long way to go, will require a lot of support en route, and are of course high risk. Discovery is hard, so let’s keep our fingers crossed!

Second, would you like to help fund a movie about antibiotic resistance? Bill Mudge, Jean Mudge, and Bob Milley are co-producers at Recombinant Films LLC. They have been steadily pulling together a internationally targeted documentary entitled Beating SuperBugs: Can We Win? for a generally educated but uninitiated audience. The documentary will focus on four of the CDC’s top superbug threats: tuberculosis; MRSA; C. difficile; and CRE. 

Using funds from a 2015 Kickstarter campaign, the team are now within about $100k of completing the film for release. If you’d like to help them get to done, you can make a tax-deductible contribution through their 501(c)3, non-profit fiscal sponsor, Catticus Corporation, Berkeley, CA. I think that non-technical material of this type is really valuable and I’m sure they’d appreciate any amount you might send.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://13.43.35.2/blog/

Upcoming meetings of interest to the AMR community:

Share

Conflict-Borne XDR Superbugs: It’s Time for the PASTEUR Act!

Dear All: The recent publication of an exceptionally good plain-language summary of the AMR problem in Rolling Stone (yes, you read that correctly!) prompts today’s 3-part journey into the way(s) that war contributes to the threat of resistant superbugs. We’ve summarized the story in outline form — please explore the references for further details. And

ENABLE-2 funding now includes Hit Identification & Validation

23 July 2024 addenda x 2:  Mark Blaskovich let me know that the CO-ADD project is still offering a free in vitro screening service. See https://www.co-add.org/ to submit compounds for free testing vs 5 bacteria and 2 fungi; see https://db.co-add.org/ for structures and screening data on >100K compounds. The GHIT Fund has announced its 21st Request for Proposals for its Hit-to-Lead Platform to

NIAID/DMID thinking for FY2026: Antibacterials, Phage, and Antifungals

Dear All, NIAID’s DMID (Division of Microbiology and Infectious Diseases) recently held a council meeting during which they proposed program concepts that encompassed both antibacterial therapies (including phage) as well as antifungal therapies for funding in FY 2026 (the year that would run from 1 Oct 2025 to 30 Sep 2026). There is no guarantee that

WHO Antibacterial Pipeline Review: Update thru 31 Dec 2023

Dear All, WHO have released an update through 31 Dec 2023 of their ongoing series of antibacterial pipeline reviews! Here are the links you need: The report: 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis and a press release about the report. Infographics: Key facts and recommendations from the 2023 antibacterial agents in clinical

Scroll to Top